Table 7 Profile of PALUFER trial activities evaluating weekly iron supplementation [21]

Screening

Demographics^b

-

-

-

-

Randomisation

Reproductive,^c general health, blood pressure, temperature, dietary,^e drugs

Sera for iron biomarkers,^d Hb if pallor or symptomatic

Blood for sera and genotype

Wt, Ht, BMI, MUAC

Malaria if symptomatic, vaginal, STI (syndromic)

Non-pregnant cohort

- Weekly visits^f

T⁰ C and morbidity,^g side effects, compliance,

-

-

-

RDT for malaria if symptoms/febrile

- Cross-sectional survey

T⁰ C and morbidity, side effects

-

-

-

All for malaria microscopy

- Participant unscheduled visits

T⁰ C and morbidity, side effects

-

-

-

If symptoms

- End assessment survey

T⁰ C and morbidity, side effects

Hb, iron biomarkers

Nutritional biomarkers^h

Wt, Ht, MUAC

Malaria RDT and microscopy, BV, CRP, vaginal microbiome and lactoferrin, trichomonas

-Focus groups/interviews

Knowledge and acceptability

-

-

-

-

Pregnant cohort

- First AN attendance ⁱ at 13–16 wks

T⁰ C and morbidity, ultrasound, blood pressure, drugs (IPTp), supplement, compliance, side effects

Hb, iron and folate biomarkers

Urine glucose and protein

Wt, Ht, MUAC

Malaria RDT and microscopy, CRP and AGP, BV, HIV, STI (syndromic), vaginal lactoferrin and microbiome, trichomonas

- Second AN attendance at 32–36 wks

T⁰ C and morbidity, blood pressure, drugs (IPTp)

Hb if pallor or symptomatic

Urine glucose and protein

Wt, Ht

Vaginal lactoferrin and microbiome, other infections if symptoms

- Unscheduled visits

T⁰ C and morbidity

Hb if pallor or symptomatic

-

Wt

Other infections if symptoms

- Delivery

T⁰ C and morbidity, stillbirths

-

-

Wt

Placental histology for chorioamnionitis and malaria

Infant follow-up

-Live births

Gestational age

-

-

Wt, length, HC

-

-Cross-sectional postnatal survey

Infant feeding, morbidity, health visits

Hb, iron biomarkers

-

Wt, length, MUAC

Malaria